Leland Gershell
Stock Analyst at Oppenheimer
(4.55)
# 256
Out of 5,147 analysts
152
Total ratings
50.69%
Success rate
31.23%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $98 → $95 | $61.73 | +53.90% | 4 | Feb 24, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $246 → $262 | $233.50 | +12.21% | 13 | Feb 12, 2026 | |
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $54.94 | +415.11% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $12.49 | +180.22% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $27.93 | +93.34% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $11.92 | +101.34% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $10.11 | +226.41% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $6.12 | +194.12% | 6 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $29.38 | +22.53% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $41.10 | +111.68% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $23.45 | +241.15% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $110 | $39.07 | +181.55% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $66.48 | -8.24% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $332.92 | +47.18% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $7.18 | +178.55% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $92.73 | +18.62% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $21.70 | +42.86% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $7.15 | +39.86% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $766.92 | -7.68% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $0.13 | +7,855.45% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $55.19 | -5.78% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $198.31 | -25.87% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.58 | +1,837.98% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $27.73 | +91.13% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.10 | +192.68% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $2.17 | +230,314.75% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $6.36 | +293.08% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $0.52 | +3,773.72% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $23.08 | +25.65% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $17.50 | +100.00% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.28 | +3,470.15% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.68 | +2,862.96% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.71 | +660.23% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.44 | +3,388.37% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.23 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $33.86 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $13.80 | - | 5 | Mar 31, 2020 |
BioMarin Pharmaceutical
Feb 24, 2026
Maintains: Outperform
Price Target: $98 → $95
Current: $61.73
Upside: +53.90%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $246 → $262
Current: $233.50
Upside: +12.21%
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $54.94
Upside: +415.11%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $12.49
Upside: +180.22%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $27.93
Upside: +93.34%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $11.92
Upside: +101.34%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $10.11
Upside: +226.41%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $6.12
Upside: +194.12%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $29.38
Upside: +22.53%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $41.10
Upside: +111.68%
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $23.45
Upside: +241.15%
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $39.07
Upside: +181.55%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $66.48
Upside: -8.24%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $332.92
Upside: +47.18%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $7.18
Upside: +178.55%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $92.73
Upside: +18.62%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $21.70
Upside: +42.86%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $7.15
Upside: +39.86%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $766.92
Upside: -7.68%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $0.13
Upside: +7,855.45%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $55.19
Upside: -5.78%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $198.31
Upside: -25.87%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.58
Upside: +1,837.98%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $27.73
Upside: +91.13%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.10
Upside: +192.68%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $2.17
Upside: +230,314.75%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $6.36
Upside: +293.08%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $0.52
Upside: +3,773.72%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $23.08
Upside: +25.65%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $17.50
Upside: +100.00%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.28
Upside: +3,470.15%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.68
Upside: +2,862.96%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.71
Upside: +660.23%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.44
Upside: +3,388.37%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.23
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $33.86
Upside: -
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $13.80
Upside: -